Johannes Brägelmann (@braegelmannlab) 's Twitter Profile
Johannes Brägelmann

@braegelmannlab

Physician & biostatistician. Excited about cancer research, tumor evolution & functional genomics, driven to improve cancer therapy

ID: 1431003907812204545

linkhttp://www.braegelmannlab.com calendar_today26-08-2021 21:21:56

144 Tweet

116 Takipçi

150 Takip Edilen

Niklas Klümper (@niklas_kluemper) 's Twitter Profile Photo

Happy to share our novel manuscript on "Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer" ➡️efficacy of ADC for active cerebral metastases has been demonstrated already

Happy to share our novel manuscript on "Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer" 

➡️efficacy of ADC for active cerebral metastases has been demonstrated already
Niklas Klümper (@niklas_kluemper) 's Twitter Profile Photo

Very happy to share our letter published European Urology ➡️Membranous expression of target protein is required for ADC response in urothelial cancer sciencedirect.com/science/articl… Thanks to the great co-authors Markus Eckstein Christoph Kuppe Johannes Brägelmann Viktor Grünwald

Very happy to share our letter published <a href="/EUplatinum/">European Urology</a> 
➡️Membranous expression of target protein is required for ADC response in urothelial cancer

sciencedirect.com/science/articl…

Thanks to the great co-authors <a href="/Markuseckstein3/">Markus Eckstein</a> <a href="/KuppeChristoph/">Christoph Kuppe</a> <a href="/braegelmannlab/">Johannes Brägelmann</a> <a href="/ViktorGruenwald/">Viktor Grünwald</a>
OncoAlert (@oncoalert) 's Twitter Profile Photo

Next-generation lung cancer pathology: Development and validation of diagnostic and prognostic algorithms out on Cell Study presents a computational🖥️🔬 pathology platform for non-small cell #LungCancer 🫁 #NSCLC ) that aids in patient care optimization and

Next-generation lung cancer pathology: Development and validation of diagnostic and prognostic algorithms out on <a href="/CellCellPress/">Cell</a> 

Study presents a computational🖥️🔬 pathology platform for non-small cell #LungCancer 🫁 #NSCLC ) that aids in patient care optimization and
Department of Translational Genomics (@dtg_cologne) 's Twitter Profile Photo

Cologne Conference on Lung Cancer June 26-27, 2025 On behalf of the conference chair Caroline Dive and the organizing committee Reinhard Buettner, Roman Thomas, Juergen Wolf we are pleased to share news about the next CCLC #CCLC #Networking #Conference2025 #lungcancer #cologne

Cologne Conference on Lung Cancer June 26-27, 2025

On behalf of the conference chair Caroline Dive and the organizing committee Reinhard Buettner, Roman Thomas, Juergen Wolf we are pleased to share news about the next CCLC

#CCLC #Networking #Conference2025 #lungcancer #cologne
Uromigos (@uromigos) 's Twitter Profile Photo

😱 Don't get spooked by new data - watch the #UromigosLive24 panel on novel ADCs in urothelial carcinoma discussed by Tom Powles, Andrea Apolo, M.D., Petros Grivas, Shilpa Gupta, and KSridhar. 🔬 Learn about a new study from Dr. Yohann Loriot of Gustave Roussy on BT8009, HER3, and

😱 Don't get spooked by new data - watch the #UromigosLive24 panel on novel ADCs in urothelial carcinoma discussed by <a href="/tompowles1/">Tom Powles</a>, <a href="/apolo_andrea/">Andrea Apolo, M.D.</a>, <a href="/PGrivasMDPhD/">Petros Grivas</a>, <a href="/shilpaonc/">Shilpa Gupta</a>, and <a href="/kalasri3/">KSridhar</a>.

🔬 Learn about a new study from Dr. Yohann Loriot of <a href="/GustaveRoussy/">Gustave Roussy</a> on BT8009, HER3, and
Markus Eckstein (@markuseckstein3) 's Twitter Profile Photo

Happy to share our poster #SABCS24 SABCS: In heavily pretreated breast cancer from the Phase 1/2 Duravelo-1 trial, pts with NECTIN4 amplification had a 57.1% ORR with zelenectide pevedotin (Zele, formerly BT8009) vs. ~6.3% in non-amp. Notably, responses were seen even

Happy to share our poster #SABCS24 <a href="/SABCSSanAntonio/">SABCS</a>: In heavily pretreated breast cancer from the Phase 1/2 Duravelo-1 trial, pts with NECTIN4 amplification had a 57.1% ORR with zelenectide pevedotin (Zele, formerly BT8009) vs. ~6.3% in non-amp. Notably, responses were seen even
Markus Eckstein (@markuseckstein3) 's Twitter Profile Photo

🚨 New preprint drop! MOSAIC builds a pan-cancer spatial + single-cell multi-omics atlas of thousands of tumors, exposing the fine-grained mosaic of intra-tumoral heterogeneity and immune niches. A game-changer for #PrecisionOncology and data-hungry AI models. More to come (much

Patrizia Giannatempo (@giannatempopatr) 's Twitter Profile Photo

ASCO25 Zelenectide vedotin (BT8009) + pembro: ORR 65% (25% CR) in 1L cis-ineligible la/mUC (incl. PS 2). 👉#bicycle toxin conjugate (small peptide) targeting Nectin-4, with renal clearance (vs hepatic for EV). 👆Encouraging tolerability Matt Galsky Ignacio Duran Andrea Necchi

ASCO25 Zelenectide vedotin (BT8009) + pembro: ORR 65% (25% CR) in 1L cis-ineligible la/mUC (incl. PS 2).
👉#bicycle toxin conjugate (small peptide) targeting Nectin-4, with renal clearance (vs hepatic for EV). 
👆Encouraging tolerability <a href="/MattGalsky/">Matt Galsky</a> <a href="/nachoduranm/">Ignacio Duran</a> <a href="/AndreaNecchi/">Andrea Necchi</a>
Johannes Brägelmann (@braegelmannlab) 's Twitter Profile Photo

Excited to share our paper on AI-based prediction of disease progression in squamous skin cancers in npj Journals! Great collaboration w Juan Pisula & Kasia Bozek using federated learning & explainable AI for high accuracy while preserving patient privacy: nature.com/articles/s4169…

Niklas Klümper (@niklas_kluemper) 's Twitter Profile Photo

New NECTIN4 FISH probe now enables broader testing of NECTIN4 amplification across solid tumors! ➡️promising genomic biomarker for anti-NECTIN4 targeting therapies! 📈 NECTIN4 amp predicts response to: - Enfortumab vedotin in mUC Journal of Clinical Oncology 2024 - novel Bicycle-Drug Conjugate

Niklas Klümper (@niklas_kluemper) 's Twitter Profile Photo

NECTIN4 amplification predicts anti-Nectin4 therapy response! 🎯 NECTIN4 amp predicts: - Enfortumab vedotin response in mUC Journal of Clinical Oncology ASCO ascopubs.org/doi/full/10.12… & Zelenectide pevedotin (Bicycle-Drug Conjugate) response in TNBC SABCS + NSCLC-> now being tested in

CancerNetwork® (@cancernetwrk) 's Twitter Profile Photo

The confirmed overall response rate with ABB-706 was 77% in patients with relapsed/refractory small cell lung cancer who received 2 prior lines of therapy. hubs.li/Q03JbwVr0 #SCLC #lcsm #WCLC25 | Lauren Averett Byers, MD

Hunter Shain (@shainlab) 's Twitter Profile Photo

STmut is now working on Visium HD data! Infer copy number from spatial transcriptomics data at unparalleled accuracy and resolution

STmut is now working on Visium HD data! Infer copy number from spatial transcriptomics data at unparalleled accuracy and resolution
Benjamin D. Greenbaum (@bengrbm) 's Twitter Profile Photo

Sharing a paper below in Cell Genomics that took us literally 10 years+ (!) to write on the topics of 👇👇👇 * How, exactly, do we quantify viral mimicry - the expression of molecular features usually associated with nonself viruses by our own "self" cells? * Why do we see

Sharing a paper below in <a href="/CellGenomics/">Cell Genomics</a> that took us literally 10 years+ (!) to write on the topics of 👇👇👇

*  How, exactly, do we quantify viral mimicry - the expression of  molecular features usually associated with nonself viruses by our own  "self" cells? 

* Why do we see